Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment

Sabbioni, Marzio; Siegrist, H P; Bacchi, M.; Bernhard, Jürg; Castiglione, M.; Thürlimann, Beat; Bonnefoi, Hervé; Perey, L; Herrmann, Richard; Goldhirsch, Aron; Hürny, Christoph

doi:10.1023/a:1006379925343

Cited by 24 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Klein et al (1991) proved the correlation between B2-M and clinical course of disease in 365 women with breast cancer. Also Sabbioni et al (2000) observed some impact of subjective burden in patients with early breast cancer on soluble immune measures, including B2-M and sIL-2R , determined serially during and after chemotherapy. Stefanovic et al (1999) have observed the signiWcant decrease of the elevated pretreatment serum B2-M values following resection of the tumour in patients with urothelial carcinoma.…”

Section: B2-mmentioning

confidence: 92%

The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas

Bień

Rąpała

Krawczyk

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

sIL-2R alpha and LDH were [corrected] proven to be promising markers [corrected] for diagnosis and treatment monitoring in children with STS. The markers [corrected] correlated also with some [corrected] important prognostic clinico-pathological factors for childhood [corrected] STS; however, they [corrected] failed to predict EFS and OS. Measurements of serum [corrected] B2-M were shown [corrected] to have no clinical value in the diagnostics, prognostics and treatment monitoring in paediatric STS.

show abstract

Section: B2-mmentioning

confidence: 92%

The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas

Bień

Rąpała

Krawczyk

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…In contrast, solid malignancies usually are not associated with elevations in serum sCD25 unless the disease has disseminated [48][49][50][51]. Elevated sCD25 levels in the ascites of ovarian cancer patients and in the serum of breast cancer patients correlated with a low frequency of TILs, suggesting that sCD25 could inhibit antitumor immunosurveillance [52]. sCD25 suppresses IL-2-induced surface CD25 expression and T cell responses in vitro [30,31,[53][54][55].…”

Section: -Test) (F)mentioning

confidence: 99%

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Hannani¹,

Vétizou²,

Enot³

et al. 2015

Cell Res

144

111

View full text Add to dashboard Cite

The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces immune-mediated longterm control of metastatic melanoma in a fraction of patients. Although ipilimumab undoubtedly exerts its therapeutic effects via immunostimulation, thus far clinically useful, immunologically relevant biomarkers that predict treatment efficiency have been elusive. Here, we show that neutralization of IL-2 or blocking the α and β subunits of the IL-2 receptor (CD25 and CD122, respectively) abolished the antitumor effects and the accompanying improvement of the ratio of intratumoral T effector versus regulatory cells (Tregs), which were otherwise induced by CTLA-4 blockade in preclinical mouse models. CTLA-4 blockade led to the reduction of a suppressive CD4 + T cell subset expressing Lag3, ICOS, IL-10 and Egr2 with a concomitant rise in IL-2-producing effector cells that lost FoxP3 expression and accumulated in regressing tumors. While recombinant IL-2 improved the therapeutic efficacy of CTLA-4 block-

show abstract

“…Thus, we consider that IL-19 produced by breast cancer cells promotes tumor progression not only by its autocrine effect but also by providing a microenvironment for tumor growth and metastasis. Furthermore, cytokines are mediators of the effector response from innate and acquired cellular immunities (49,50); they are probably involved in the mechanism for tumor cell evasion in the immunosurveillance system. This might also be one of the mechanisms by which overexpression of IL-19 in breast cancer cells promoted tumor growth and metastasis in vivo.…”

Section: Discussionmentioning

confidence: 99%

Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome

Hsing

Cheng

Hsu

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Interleukin (IL)-19 was expressed in invasive ductal carcinoma (IDC) of the breast tissue but not in healthy breast tissue. We explored the effects of IL-19 on the pathogenesis of breast cancer and its clinical outcome. Experimental Design: Tumor expression of IL-19 was assessed by immunohistochemistry and/or real-time quantitative PCR between two groups of patients with breast IDC (n = 60 and 143, respectively) with available clinical and survival data. We examined the effects of IL-19 on cytokine and chemokine production as well as proliferation and migration in breast cancer cells. Mice were injected with IL-19–overexpressing or vector control 67NR cells and the tumor growth and lung metastatic micronodules were measured. Results: Of the IDC specimens, high IL-19 expression was associated with advanced tumor stage, high tumor metastasis, and worse survival. In vitro, IL-19 induced transcripts of IL-1β, IL-6, TGF-β, matrix metalloproteinase (MMP)2, MMP9, and CXCR4 in 4T1 breast cancer cells; induced fibronectin expression and assembly; and promoted cancer cell proliferation and migration, which were inhibited by anti-IL-19 monoclonal antibody (mAb). Endogenous fibronectin expression and cancer cell migration were lower in IL-19 knockdown 4T1 cells. In 4T1 cells, hypoxia induced IL-19 and CXCR4 expression, which was inhibited by anti-IL-19 mAb. IL-19 overexpression in noninvasive 67NR cancer cells increased cell proliferation and migration. In vivo, mice injected with IL-19–overexpressing 67NR cell clones showed larger tumors and more metastatic micronodules in the lung. Conclusions: High IL-19 expression in breast cancer tissue is associated with a poor clinical outcome. IL-19 is pivotal in the pathogenesis of breast cancer. Clin Cancer Res; 18(3); 713–25. ©2011 AACR.

show abstract

Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment

Cited by 24 publications

References 29 publications

The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas

The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome

Contact Info

Product

Resources

About